RT Journal Article
SR Electronic
T1 Altered Cerebral Blood Flow in Older Adults with Alzheimer’s Disease: A Systematic Review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.24.22272916
DO 10.1101/2022.03.24.22272916
A1 Swinford, Cecily G.
A1 Risacher, Shannon L.
A1 Wu, Yu-Chien
A1 Apostolova, Liana G.
A1 Gao, Sujuan
A1 Saykin, Andrew J.
YR 2022
UL http://medrxiv.org/content/early/2022/03/25/2022.03.24.22272916.abstract
AB The prevalence of Alzheimer’s disease is projected to reach 13 million in the U.S. by 2050. Although major efforts have been made to avoid this outcome, so far there are no treatments that can stop or reverse the progressive cognitive decline that defines Alzheimer’s disease. The utilization of preventative treatment before significant cognitive decline has occurred may ultimately be the solution, necessitating a reliable biomarker of preclinical/prodromal disease stages to determine which older adults are most at risk. Quantitative cerebral blood flow is a promising potential early biomarker for Alzheimer’s disease, but the spatiotemporal patterns of altered cerebral blood flow in Alzheimer’s disease are not fully understood. The current systematic review compiles the findings of 29 original studies that compared quantitative cerebral blood flow in older adults with mild cognitive impairment or Alzheimer’s disease to that of cognitively normal older adults and/or assessed the relationship between cerebral blood flow and objective cognitive function. Individuals with Alzheimer’s disease had relatively decreased cerebral blood flow in all brain regions investigated, especially the temporoparietal and posterior cingulate, while individuals with mild cognitive impairment had less consistent results, with relatively increased cerebral blood flow reported in the temporal lobe and thalamus. Most papers reported a positive correlation between cerebral blood flow and cognitive function. This review highlights the need for more studies comparing cerebral blood flow between cognitively normal individuals and those with mild cognitive impairment, as well as the importance of including potential confounding factors in these analyses.Competing Interest StatementDr. Apostolova receives support in the form of consulting fees from Biogen, Two Labs, IQVIA, NIH, Florida Department of Health, NIH Biobank, Eli Lilly, GE Healthcare, and Eisai; in the form of payment for lectures, etc. from AAN, MillerMed, AiSM, and Health and Hospitality; and in the form of travel and meeting support from Alzheimer's Association. She also participates on Data Safety Monitoring or Advisory boards for IQVIA, NIA R01 AG061111, UAB Nathan Shock Center, and New Mexico Exploratory ADRC; in leadership roles for Medical Science Council Alzheimer Association Greater IN Chapter, Alzheimer Association Science Program Committee, and FDA PCNS Advisory Committee; stock or stock options Cassava Neurosciences and Golden Seeds, and receipt of materials, etc. from AVID Pharmaceuticals, Life Molecular Imaging, and Roche Diagnostics. Dr. Saykin serves with Bayer Oncology (Scientific Advisory Board), Eisai (Scientific Advisory Board), Siemens Medical Solutions USA, Inc. (Dementia Advisory Board), and Springer-Nature Publishing (Editorial Office Support as Editor-in-Chief, Brain Imaging and Behavior). All other authors report no disclosures.Funding StatementDr. Risacher receives support from the National Institute on Aging (K01 AG049050, R01 AG061788) and the New Vision Award. Dr. Wu receives support from the National Institute on Aging (R01 AG053993). Dr. Apostolova receives support from NIH, Alzheimer Association, AVID Pharmaceuticals, Life Molecular Imaging, and Roche Diagnostics. Dr. Saykin receives support from multiple NIH grants (P30 AG010133, P30 AG072976, R01 AG019771, R01 AG057739, U01 AG024904, R01 LM013463, R01 AG068193, T32 AG071444, and U01 AG068057 and U01 AG072177). He has also received support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly (in kind contribution of PET tracer precursor).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe did not analyze or generate datasets because this work involved the compilation and synthesis of previously published results, all of which are cited and available to view.